Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers

Abstract

The interaction between tyramine and the new short-acting and reversible mono amine oxidase inhibitor moclobemide was investigated in a double-blind placebo-controlled study in six healthy volunteers. There were two consecutive study periods of 8 days during which the subjects received moclobemide three x 200 mg daily or placebo. On day 5 of each study period changes in systolic blood pressure (SBP) were determined after incremental intravenous bolus doses of tyramine and on days 6, 7 and 8 changes in SBP were determined after oral tyramine (100, 200 and 300 mg, respectively). Oral tyramine was administered together with a standard breakfast, before which moclobemide had been given. On days 5- 8 blood was taken for determination of blood drug levels. On days 6-8 blood samples were taken before and at 15, 30 and 45 min after tyramine administration for determination of plasma tyramine and plasma norepinephrine concentrations. When SBP had increased by approximately 30 mmHg no further doses of either intravenous or oral tyramine were given. Moclobemide was well tolerated by all subjects. Plasma trough levels of moclobemide were within the therapeutic range. The tyramine induced increases in SBP were greater during moclobemide than during placebo. After intravenous tyramine the dose-response curve for SBP was shifted to the right by a factor of approximately 3. When compared to placebo the pressor response to 100 mg tyramine orally was not significantly different, but the pressor response to the other two doses was enhanced during moclobemide.

Get full access to this article

View all access options for this article.

References

Abeling N.G. , van Gennip A.H. , Overmars H. , Voûte P.A. 1984

Simultaneous determination of catecholamines and metanephrines in urine by HPLC with fluorometric detection

Clin Chim Acta 137: 211-226

Blackwell B. 1963 Hypertensive crisis due to monoamine oxidase inhibitors . Lancet 2: 849-851

Blackwell B. , Marlow E. , Price J. , Taylor D. 1967 Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiat 113: 349-365

Da Prada M. , Keller H.H. , Kettler R. , Schaffner R. , Pieri M. , Buckhard W.P. , Korn A. , Haefely W.E. 1982 Ro 11-1163, a specific and short-acting MAO inhibitor with antidepressant properties. In: Monoamine oxidase, basic and clinical frontiers (eds Kamijo K, Usdin E, Nagatsu T) Excerpta Medica. Amsterdam, pp 183-196

Da Prada M. , Kettler R. , Burkhard W.P. , Haefely W.E. 1984 Moclobemide, an antidepressant with short-lasting MAO-inhibition : brain catecholamines and tyramine pressor effects in rats. In: Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors (eds Tipton K F, Dostert P, Benedetti M S) 88: Academic Press, London, pp 137-155

Da Prada M. , Zürcher G. , Wüthrich I. , Haefely W.E. 1988 On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 26 Suppl: 33-56

Dollery C.T. , Brown M.J. , Davies D.S. , Lewis P.J. , Strolin-Benedetti M. 1983 Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase. Clin Pharmacol Ther 34: 651-662

Folkow B. , DiBona G. , Hjemdahl P. , Thoren P.H. , Wallin B.G. 1983 Measurement of plasma norepinephrine concentrations in human primary hypertension: a word of caution on their applicability for assessing neurogenic contributions. Hypertension 5: 399-403

Gieschke R. , Körner J. , Eggers H. 1987 Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high performance liquid chromatography. J Chromatogr Biomed Appl 420: 111-120

10.

Gieschke R. , Schmidt-Burgk W. , Amrein R. 1988 Interaction of moclobemide, a new reversible monoamine oxidase inhibitor, and oral tyramine. J Neural Transm 26 Suppl: 97-104

11.

Goldberg L.I. 1964 Monoamine oxidase inhibitors: adverse reactions and possible mechanisms. J Am Med Assoc 190: 456-462

12.

Horwitz D. , Lovenberg W. , Engelman K. , Sjoerdsma A. 1964 Monoamine oxidase inhibitors, tyramine and cheese. J Am Med Assoc 188: 1108

13.

Korn A. , Eichler H.G. , Fischbach R. , Gasic S. 1986 Moclobemide, a new reversible MAO inhibitor: interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology 88: 153-157

14.

Korn A. , Da Prada M. , Raffesberg W. , Gasic S. , Eichler H.G. 1988a Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 11: 17-23

15.

Korn A. , Da Prada M. , Raffesberg W. , Allen S. , Gasic S. 1988b Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neurol Transm 26 Suppl: 57-71

16.

Müller T. , Gieschke R. , Ziegler W.H. 1988 Blood pressure response to tyramine-enriched meal before and during MAO inhibition in man. Influence of dosage regimen. J Neural Transm 26 Suppl: 105-114

17.

Peuler J.D. , Johnson G.A. 1977

Simultaneous single isotope radio-enzymatic assay of plasma norepinephrine, epinephrine and dopamine

Life Sci 21: 625-636

18.

Wiesel F.A. , Raaflaub J. , Kettler R. 1985 Pharmacokinetics of oral moclobemide in healthy human subjects and effects of MAO activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol 28: 89-95

19.

Young M. 1981 The significance of biogenic amines in food and beverages . Aust J Pharm Sci 10: 1-8